AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03349866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 bid d1-14
Study NCT03349866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2 Ivgtt d1 q3w
Study NCT03349866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 Ivgtt d1 q3w
Study NCT00809627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine 500 mg IV
Study NCT03349866 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 45Gy/25f （1.8Gy/f/d，5 f/w）
Study NCT03349866 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45Gy/25f （1.8Gy/f/d，5 f/w）
Study NCT03926962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 4873
Description: 100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)
Study NCT03926962 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Visually matching placebo
Study NCT00868673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low fructose
Description: patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
Study NCT00868673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal fructose arm
Description: patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
Study NCT04852510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Versus a combination of Metformin and Thymoquinone (TQ)
Description: Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
Study NCT04254874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abidol hydrochloride
Description: 0.2g once, 3 times a day,two weeks
Study NCT04254874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abidol Hydrochloride combined with Interferon atomization
Description: Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
Study NCT05008250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongmai Yangxin Pill (TMYXP)
Description: TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
Study NCT02008409 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoLift Liver Retractor
Description: During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends.
Study NCT01498185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 1 mg, Once daily, 14 days
Study NCT01498185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Dapagliflozin
Description: Tablets, Oral, 0 mg, Once daily, 14 days
Study NCT00946322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-Based Treatment for Alcohol Use Disorders and PTSD
Description: This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
Study NCT02559661 — intervention group
Intervention type: OTHER
Intervention: Training on a virtual simulator in eye surgery
Study NCT00809627 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Normal saline
Study NCT03663361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMART Intervention
Description: Ankle rehabilitation with the addition of sensorimotor components
Study NCT03663361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Intervention
Description: Ankle rehabilitation focused on restoring range of motion, strength and balance
Study NCT04531345 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
Study NCT02709239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA 200mg
Description: 4 50mg capsules of DHA to be taken by mouth daily
Study NCT02709239 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA 800mg
Description: 4 200mg capsules of DHA to be taken by mouth daily
Study NCT04006821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
Study NCT04006821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate
Description: Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
Study NCT03205904 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Nutrition booklet with guidelines on types of fats and glycemic index
Study NCT05008250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metoprolol tartrate
Description: metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
Study NCT05008250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol tartrate
Description: metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
Study NCT05008250 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: simulated pills
Study NCT02577211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hipocaloric enteral nutrition
Description: 15 kcal/Kg of body weight
Study NCT02577211 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normocaloric enteral nutrition
Description: 25 kcal/kg of body weight
Study NCT03889548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
Study NCT04660227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Trainning
Description: Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour. Before starting the exercise, the risk of possible injury will be minimized by doing warm-up exercises and preparations will be made to start the exercise. Then, the exercise program will be started with aerobic exercise. Strengthening exercises will be planned for large muscle groups, targeting body parts such as hips, knees, shoulders, abdomen and trunk. In exercises, it is planned to do 2 sets of 10-15 repetitions using elastic band, free weights or body weight. The exercise program will be created according to the condition of the people and progression will be provided every 2 weeks. After the exercises are completed, cool down will be done with relaxation and stretching exercises.
Study NCT04660227 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks. After the final evaluations, they will be directed to the exercise group.
Study NCT02087527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
Study NCT02087527 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IV normal saline every 6 hours for 48 hours
Study NCT01755884 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat oral immunotherapy
Description: Cooked spaghetti
Study NCT01019642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 4,000 IU per day during 6 months. Capsule form.
Study NCT01019642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no active principles given.
Study NCT00849602 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid for three days
Study NCT00849602 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine bid for three days
Study NCT02986100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-14 labeled Rucaparib
Description: Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib
Study NCT02986100 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 200 \& 300 mg tablet
Study NCT04079543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NPO past midnight
Description: NPO after midnight (solids and liquids), except for a sip of water with medication.
Study NCT04079543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: NPO
Description: No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
Study NCT03514498 — intervention group
Intervention type: PROCEDURE
Intervention: Dental surgery
Description: All types of dental surgery
Study NCT02386904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Enema (Kleen® Enema)
Description: 120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
Study NCT01526616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg twice a day for six months
Study NCT01526616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin plus Spironolactone
Description: Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
Study NCT03070574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine 2400 MG (5-ASA)
Description: For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
Study NCT03070574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine 1200 MG
Description: For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
Study NCT03070574 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
Study NCT03070574 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
Study NCT02202642 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collagenase
Description: Cultured limbal stem cells transplantation
Study NCT00388726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice
Description: Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
Study NCT02584257 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methacholine chloride
Study NCT02584257 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: methacholine chloride
Study NCT02584257 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: methacholine chloride
Study NCT02584257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo ProAir HFA
Study NCT02584257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo ProAir HFA
Study NCT02584257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ProAir HFA
Study NCT02584257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAir HFA
Study NCT02584257 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupin albuterol HFA MDI
Study NCT04179695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consulting with PARKINSUN as communication aid-tool
Description: Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months
Study NCT04179695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consulting without PARKINSUN as communication aid-tool
Description: Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
Study NCT01251549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk - a motorized exoskeleton suit
Description: The subject will wear the ReWalk suit and have training sessions for walking with the device
Study NCT03933150 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasound guided caudal epidural injection
Description: A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor
Study NCT00947973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program (CHP) after-school model
Description: Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
Study NCT00947973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program (CHP) consultation model
Description: Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
Study NCT02160158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine ER (fasted)
Description: Commercial Fesoterodine ER 4 mg (single dose)
Study NCT02160158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR3 (fasted)
Description: Fesoterodine SR3 4 mg (single dose)
Study NCT02160158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR3 (fed)
Description: Fesoterodine SR3 4 mg (single dose) with high-fat meal
Study NCT02160158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine ER (fed)
Description: Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
Study NCT02160158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR3 (sprinkle)
Description: Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
Study NCT02160158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR4 (fasted)
Description: Fesoterodine SR4 4 mg (single dose)
Study NCT02160158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR4 (fed)
Description: Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
Study NCT02160158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fesoterodine SR4 (sprinkle)
Description: Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
Study NCT04051047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
Study NCT04051047 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor biopsy and blood draw
Description: As part of standard of care, all participants will undergo tumor biopsy and collection of peripheral blood.
Study NCT04600674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping
Description: DCC performed at 60 sec after birth
Study NCT04600674 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early cord clamping
Description: ECC performed at 15 sec after birth
Study NCT02440477 — intervention group
Intervention type: OTHER
Intervention: clinical shoulder tests
Description: Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
Study NCT00621829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA enriched fish oils
Description: Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
Study NCT00621829 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPA enriched fish oils
Description: Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.